Cartesian Therapeutics, Inc. (RNAC) Total liabilities 2016–2025
Cartesian Therapeutics, Inc. (RNAC) total liabilities at each fiscal year-end, per SEC filings.
$422.7MFY2025 · since FY2016: $34.3M → $422.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $422.7M | -4.3% |
| FY2024 | $441.8M | -0.6% |
| FY2023 | $444.7M | +517.1% |
| FY2022 | $72.1M | -47.5% |
| FY2021 | $137.4M | -25.1% |
| FY2020 | $183.4M | +101.2% |
| FY2019 | $91.2M | +82.7% |
| FY2018 | $49.9M | +1.2% |
| FY2017 | $49.3M | +43.5% |
| FY2016 | $34.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net incomeRNAC Net marginRNAC Gross profitRNAC Gross marginRNAC Operating incomeRNAC Operating marginRNAC Operating cash flowRNAC Free cash flowRNAC Capital expendituresRNAC Return on equityRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Shareholders’ equityRNAC overview →